The FDA is warning that results from a clinical trial show a possible increased risk for death with use of the PI3 kinase inhibitor duvelisib (Copiktra, Secura Bio) compared with the monoclonal antibody ofatumumab (Kesumpta, Novartis) for the treatment of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The trial also found that duvelisib was associated with a higher risk for serious side effects, including infections, diarrhea, inflammation of the intestines and
JULY 6, 2022